Iranian Red Crescent Medical Journal

Published by: Kowsar

Long-Term Survival in the Concomitant Evolution of Two Cancers: The Idiopathic Myelofibrosis and the Clear Cell Renal Carcinoma; A Case Report

Alina Benea 1 , Adrian Penciu 2 and Laurentiu Nedelcu 3 , *
Authors Information
1 Department of Haematology, Clinical Emergency Hospital, Brasov, Romania
2 Department of Pathology, Clinical Emergency Hospital, Brasov, Romania
3 Department of Internal Medicine, University Transilvania, Brasov, Romania
Article information
  • Iranian Red Crescent Medical Journal: 21 (5); e90077
  • Published Online: May 21, 2019
  • Article Type: Case Report
  • Received: January 30, 2019
  • Revised: April 27, 2019
  • Accepted: April 30, 2019
  • DOI: 10.5812/ircmj.90077

To Cite: Benea A, Penciu A, Nedelcu L . Long-Term Survival in the Concomitant Evolution of Two Cancers: The Idiopathic Myelofibrosis and the Clear Cell Renal Carcinoma; A Case Report, Iran Red Crescent Med J. Online ahead of Print ; 21(5):e90077. doi: 10.5812/ircmj.90077.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Introduction
2. Case Presentation
3. Discussion
  • 1. Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. Int Agency Res Cancer. 2017.
  • 2. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31(6):737-40. doi: 10.1016/j.leukres.2006.12.002. [PubMed: 17210175].
  • 3. Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395-8. doi: 10.1182/blood-2013-03-488098. [PubMed: 23838352]. [PubMed Central: PMC4828070].
  • 4. Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kroger N, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v85-99. doi: 10.1093/annonc/mdv203. [PubMed: 26242182].
  • 5. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-8. doi: 10.1182/blood-2009-09-245837. [PubMed: 20008785].
  • 6. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68-76. doi: 10.1002/cncr.22365. [PubMed: 17123268].
  • 7. Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: A prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264-70. doi: 10.1182/blood-2009-07-234880. [PubMed: 19812383].
  • 8. Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701-7. doi: 10.1038/leu.2016.148. [PubMed: 27211272]. [PubMed Central: PMC5399157].
  • 9. Whang YE, Godley PA. Renal cell carcinoma. Curr Opin Oncol. 2003;15(3):213-6. doi: 10.1097/00001622-200305000-00006. [PubMed: 12778014].
  • 10. Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sorensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study. Blood. 2011;118(25):6515-20. doi: 10.1182/blood-2011-04-348755. [PubMed: 22039256].
  • 11. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-32. [PubMed: 16079113].
  • 12. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system. Blood. 1996;88(3):1013-8. [PubMed: 8704209].
  • 13. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-901. doi: 10.1182/blood-2008-07-170449. [PubMed: 18988864].
  • 14. Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012;158(4):453-71. doi: 10.1111/j.1365-2141.2012.09179.x. [PubMed: 22651893].
  • 15. Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, et al. Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer. 2013;11(3):297-302. doi: 10.1016/j.clgc.2013.04.001. [PubMed: 23707221]. [PubMed Central: PMC3959735].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments